AlloVax (CRCL/AlloStim) / Immunovative - LARVOL DELTA

Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck (clinicaltrials.gov) - P2; N=12; Completed; Sponsor: Immunovative Therapies, Ltd.; Active, not recruiting ➔ Completed; Phase classification: P1/2 ➔ P2; N=52 ➔ 12

Clinical • Enrollment change • Phase classification • Trial completion

Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck (clinicaltrials.gov) - P2; N=0; Withdrawn; Sponsor: Immunovative Therapies, Ltd.; N=100 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal

An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects (clinicaltrials.gov) - P2a; N=15; Completed; Sponsor: Immunovative Therapies, Ltd.; Recruiting ➔ Completed; Phase classification: P2 ➔ P2a; N=30 ➔ 15; Trial completion date: Aug 2018 ➔ Mar 2019

Clinical • Enrollment change • Phase classification • Trial completion • Trial completion date